#ASCO22: Gilead’s Trodelvy shows slim benefit in common form of breast cancer
In March, Gilead drew ire from analysts for releasing an upbeat Q&A without any hard data for its latest Trodelvy trial, which put into question whether the big biotech’s drug would be effective in one of the most common forms of breast cancer.
Now, the data are finally here, showing that Trodelvy slightly outdid standard care in an ongoing Phase III study with over 500 patients who have HR+/HER2- metastatic breast cancer. All of the patients had already been treated with endocrine therapy and more than half had three or more previous chemotherapy regimens.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.